交易 Syndax Pharmaceuticals, Inc. - SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.最新股票文章

NVIDIA 股價預測:第三季財報與執行長交接
美國半導體巨頭 NVIDIA(NVDA)於 2026 年 11 月 17 日公布 2027 財年第三季營收達 1,158 億美元,年增 103%。深入了解第三方目標價與技術分析。過往表現並非未來結果的可靠指標。
20 小時前

台積電股價預測:第三方目標價
台灣積體電路製造公司(TSM)在2025年9月25日UTC下午4時55分報276.65美元,盤中區間介於270.91美元至282.95美元之間。
08:56, 3 11月 2026

IonQ 股價預測:第三方目標價
IonQ 開發囚禁離子量子系統,2026 年第一季調整後 EBITDA 虧損 9,680 萬美元,同時致力打造 256 量子位元系統。探索第三方 IONQ 目標價與技術分析。過往表現並非未來結果的可靠指標。
09:45, 30 10月 2026
